Glaukos Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Glaukos Bundle
Visual. Strategic. Downloadable.
Curious where Glaukos’ products land—Stars, Cash Cows, Dogs, or Question Marks? This snapshot hints at competitive strengths and capital drains, but the full BCG Matrix gives quadrant-by-quadrant clarity, data-backed moves, and ready-to-use Word + Excel files. Purchase the full report to skip guesswork and get a strategic roadmap you can act on today.
Stars
iDose TR launch momentum
FDA approval on October 19, 2023 of iDose TR (first sustained‑release prostaglandin for glaucoma) places Glaukos squarely in the growth quadrant of the BCG matrix. Strong physician interest and early 2024 commercial launches and formulary additions point to rapid uptake. The program requires near‑term cash for scale‑up, market access and post‑market data, but share‑grab potential could turn it into a cash cow.
MIGS leadership (iStent franchise)
Glaukos pioneered MIGS with the iStent (FDA approval 2012) and still controls the category narrative through first-mover reputation and broad surgeon adoption.
The market for safer, earlier glaucoma intervention is expanding as cataract-combo procedures increase, driving procedure volume growth globally.
Maintaining leadership requires heavy clinical education and surgeon training spend; holding share compounds into durable profit via recurring device demand and follow-on therapies.
Corneal cross-linking growth (iLink: Photrexa + KXL)
Keratoconus awareness and diagnosis are rising globally, and iLink (Photrexa + KXL) — FDA cleared in 2016 — is increasingly adopted as a first-line therapy for progressive disease. Reimbursement has expanded across key markets, shifting cross-linking from niche to mainstream care. Growth is solid enough to place the platform on the star side in many regions; continue seeding diagnostics and referral pathways to accelerate uptake.
Global expansion in high-growth markets
Global expansion for Glaukos remains early: outside the U.S. MIGS and corneal cross-linking penetration is low but accelerating, with international revenue making up roughly 25% of 2024 total sales (Glaukos FY2024). New public tenders, distributor upgrades, and localized clinical data can shift share quickly, but expansion is capital intensive due to regulatory approvals and field teams; when adoption inflects, markets can scale rapidly.
- FY2024 international revenue ≈ 25% of total (Glaukos)
- Capital needs: regulatory, market access, boots on ground
- Growth levers: tenders, distributor upgrades, localized data
- Adoption effect: slow build then rapid market tipping
Surgeon ecosystem & KOL flywheel
Training, peer-to-peer mentorship, and published real-world outcomes fuel preference in procedure-driven glaucoma markets; Glaukos reported full-year 2024 revenue of $357.6 million, reflecting accelerating adoption as more surgeons become fluent with its MIGS portfolio. The more trained surgeons, the more procedures follow, creating a costly but durable KOL flywheel that defends share and speeds uptake of new launches—classic star behavior.
- Trained surgeons: >3,000 by 2024
- FY2024 revenue: $357.6M
- High CAC: sustained training/investment to maintain flywheel
- Outcome data: improved adoption and repeat procedures
FDA-approved implant, BCG Stars: $357.6M, ≈25% intl
FDA approval of iDose TR (Oct 19, 2023) and broad iStent/iLink adoption place Glaukos in the BCG Stars quadrant: high growth, high share. FY2024 revenue $357.6M; international ≈25%; trained surgeons >3,000. Requires near-term capital for scale, training and market access to convert stars into cash cows.
| Metric | Value |
|---|---|
| FY2024 revenue | $357.6M |
| International | ≈25% |
| Trained surgeons | >3,000 |
| Key approval | iDose TR 10/19/2023 |
What is included in the product
Detailed Word Document
Concise BCG Matrix review of Glaukos products, identifying Stars, Cash Cows, Question Marks and Dogs with clear strategic actions.
Customizable Excel Spreadsheet
One-page Glaukos BCG Matrix that spots underperformers fast, easing portfolio decisions for founders and CFOs.
Cash Cows
Legacy iStent in cataract combo
Legacy iStent, FDA‑approved in 2012 and commercialized by Glaukos (NASDAQ: GKOS), is a mature, high‑volume cataract‑combo device with established surgical workflows and coding that support predictable procedure throughput. Incremental product enhancements sustain clinical relevance without outsized R&D spend. It consistently generates operating cashflow that funds iDose and retinal development while prioritizing stable service levels over aggressive reinvestment.
Installed KXL systems utilization
Installed KXL systems form the placed hardware base, with consumables and kit utilization driving recurring revenue; Glaukos reported approximately $330 million in 2024 revenue, reflecting stable procedure volumes. Market growth for corneal cross-linking remains steady, not spiking, and support costs are predictable, allowing small operational tweaks to lift gross margin. Focus on milking the installed base while expanding indications carefully to sustain consumable sales.
Aftermarket disposables & accessories
Blades, injectors and visco delivery tools form a reliable pull-through on Glaukos’ installed base, exhibiting low growth but high gross margins and very sticky purchasing patterns among surgeons. Limited promotion is needed beyond surgeon support and training, as repeat consumable demand drives steady cash generation. These aftermarket disposables quietly fund higher-risk R&D and market expansion initiatives.
OUS reimbursement-stable pockets
Markets with established national codes in 2024 (EU, UK, Japan, Australia) sustain dependable OUS volumes and long-standing payor acceptance, requiring minimal marketing lift once clinical and billing pathways are set. Operational focus shifts to supply reliability and tender discipline to protect margins. These pockets act as cash generators rather than growth engines.
- Reimbursement-stable OUS markets
- Low marketing lift after pathway establishment
- Prioritize supply reliability & tender discipline
- Cash generator, not growth driver
Data and training content reuse
Data and training content reuse: existing clinical evidence and evergreen training materials continue to convert, driving sustained adoption with minimal upkeep; repackaging often costs under 10% of creating new assets while preserving outcomes.
Low update costs support sales efficiency—studies show reused content can cut ramp time ~20% and reduce material spend—so let it work in the background.
- Conversion leverage: sustained clinical evidence
- Cost: repackaging <10% of new production
- Efficiency: ~20% faster rep from reuse
- Low-budget sales enablement
iStent and KXL: predictable cash cows funding bold R&D with minimal reinvestment
iStent and KXL form Glaukos cash cows: mature devices with predictable procedure throughput and recurring consumable pull‑through, funding higher‑risk R&D while requiring minimal reinvestment. 2024 revenue was about $330 million, driven by stable OUS coding pockets and high repeat consumable demand. Operational focus is supply reliability and margin protection.
| Metric | 2024 |
|---|---|
| Revenue | $330M |
| Cash‑cow products | iStent, KXL |
Full Transparency, Always
Glaukos BCG Matrix
The file you're previewing here is the final Glaukos BCG Matrix you'll receive after purchase. No watermarks, no demo content—just a fully formatted, strategy-ready report tailored to Glaukos' portfolio. It's immediately downloadable and editable, ready to present to stakeholders. What you see is exactly what you'll get.
Dogs
Non-core device SKUs with low pull-through
Non-core device SKUs at Glaukos are nice-to-have items that complicate inventory and rarely move the needle; by Pareto, roughly 20% of SKUs often drive ~80% of pull-through while the tail ties up working capital. SKU rationalization can free 10–30% of inventory value and reduce field distraction; sunset or bundle aggressively to reclaim shelf space and mindshare.
Geographies with chronic reimbursement friction
If codes don’t land after 3+ cycles, you’re pushing rope; Glaukos-like plays saw reimbursement efforts stall through 2024 in several geographies. Sales expense can quietly outpace contribution, eroding margins and turning positive unit economics negative within a year. Better to pause or partner than bleed cash; re-enter when policy shifts or new CPT/coverage appears. Monitor payor signals and re-deploy when coverage adoption crosses break-even.
Legacy iterations nearing obsolescence
Legacy iterations nearing obsolescence cannibalize upgrades—about 20% of procedure volume tied to older devices while contributing an estimated 25% higher service and QARA cost versus current platforms; continuing support invites regulatory exposure and margin erosion. Guide customers to current platforms with targeted migration programs and communications. Phase-out on a clear 12–18 month timeline with milestone-based support withdrawals.
One-off custom projects
One-off custom projects win applause but not profits for Glaukos: bespoke requests consume scarce engineering hours, deliver no scalable IP and erode product margins and focus; standardize offerings or decline politely to protect core MIGS economics. Discipline in R&D allocation beats being nice when returns are marginal.
- Tag: no-scale
- Tag: high-cost
- Tag: standardize-or-decline
Marketing channels with low surgeon engagement
Marketing channels with low surgeon engagement
Channels that don’t move procedures are vanity: 2024 benchmarks show CPMs of $10–25 look cheap but median CAC for device adoption ranges $1,200–3,500 and conversion to new procedures often <2%, so return is negative. Reallocate spend to peer-led education and proctoring; no sentimental spend.- Tag: CPM vs CAC
- Tag: <1–2% conversion
- Tag: Reallocate to peer-led education
- Tag: Cut low-engagement channels
Sunset legacy devices: free 10–30% stock, cut CAC, 12–18mo
Dogs: non-core SKUs and legacy devices tie up 20% of SKUs driving 80% pull-through, often freeable 10–30% inventory; reimbursement stalls through 2024 make sales costly (CAC $1,200–3,500, conversion <2%); legacy units incur ~25% higher service/QARA cost—pause, standardize, sunset on 12–18 month roadmap.
| Tag | Metric |
|---|---|
| no-scale | 20% SKUs → 80% pull |
| high-cost | CAC $1,200–3,500 |
| phase-out | 12–18 months |
Question Marks
Retinal sustained-delivery pipeline
Retinal sustained-delivery targets a large market—neovascular retinal disease therapies comprised a >$10 billion annual anti-VEGF market in 2024—so delivery innovation can still win despite crowded incumbents.
Clinical risk is real and payers are tightening access with outcomes-linked coverage and tendering that compress pricing and uptake.
If early pivotal data show durable control with markedly fewer injections (eg durable ≥3–6 months between doses) and clear vision benefit, scale investment aggressively; if not, cut fast to preserve capital.
Next-gen MIGS beyond trabecular bypass
Next-gen MIGS expanding beyond trabecular bypass into angle-based, suprachoroidal and combination-mechanism devices responds to surgeon demand for procedural optionality; safety expectations rose after the first-wave issues like the 2018 CyPass recall. Clinical targets remain clear: reproducible IOP reductions with low serious adverse event rates and streamlined workflows to drive adoption; without robust 2024 outcome data and simple OR integration, uptake stalls.
Pharma candidates for corneal disease
Pharma candidates targeting corneal disease sit as Question Marks: compelling adjacencies to Glaukos core cross-linking platform but entering a 2024 market crowded with generics and step edits, demanding sharp differentiation and a clean reimbursement story. Early clinical and commercial signals in 2024 will dictate scale of the bet; win quickly or walk.
Digital diagnostics and referral tools
Digital diagnostics that find the WHO-estimated ~50% of undiagnosed glaucoma patients can unlock downstream MIGS and laser procedures, but monetization and EHR/eye-clinic workflow integration remain question marks; pilots should target high-yield retina/glaucoma clinics and demonstrate a measurable lift in treated cases within defined cohorts, otherwise deprioritize.
- Pilot: high-yield clinics
- Metric: measurable lift in treated cases
- Risk: integration and reimbursement uncertainty
- Action: park if signal equals noise
Partnership-driven OUS launches
Distributors can cut OUS launch time by 6–12 months but typically take 20–40% channel margin, diluting control and revenue; if a partner delivers rapid access plus training and hits adoption KPIs, the initiative can move from question mark to star. Require tight milestones (quarterly/6–12 months) with predefined exit ramps and scale only where clinical and commercial proof appears.
- Time-to-market: -6–12 months
- Channel margin: 20–40%
- Governance: quarterly milestones + exit ramps
Retinal scale hinges on pivotal ≥3–6m durability to win in >$10B market
Question Marks: retinal sustained-delivery targets a >$10B 2024 anti-VEGF market but faces outcomes-linked payer pressure; scale only if pivotal shows durable ≥3–6m dosing and clear vision gain. Next-gen MIGS/diagnostics must prove reproducible IOP/diagnosis lift (WHO ~50% undiagnosed) or cut. Distributors speed OUS 6–12m but take 20–40% margin; require strict milestones.
| Item | 2024 data | Action |
|---|---|---|
| Retinal | >$10B market; target ≥3–6m durability | Scale if pivotal OK |
| MIGS/Diagnostics | WHO ~50% undiagnosed | Pilot; prove lift |
| Distribution | -6–12m; 20–40% margin | Milestones + exit ramps |